Reaching HbA_1c Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs

References

• . Resnick HE, Foster GL, Bardsley J, Ratnar RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29(3):531–537
   PubMed Web of Science ®Google Scholar
• . Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22(3):403–408
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2008;58:773–795
   Google Scholar
• . Stratton IM, Adler AI, Neil HA,. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163(11):1306–1316
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32( suppl 1):S13–S61
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA,. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel of type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32( suppl 1):S1–S201
   Google Scholar
• . Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb/Wilmington, DE: AstraZeneca; 2009
   Google Scholar
• . Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2007
   Google Scholar
• . Augeri DJ, Robl JA, Betebenner DA,. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48(15):5025–5037
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–386
   PubMed Web of Science ®Google Scholar
• . Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs. 2008;13(4):593–607
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008;5(2):73–94
   PubMedGoogle Scholar
• . Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):98–107
   PubMedGoogle Scholar
• . DeFronzo R, Hissa M, Garber AJ,. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Jadzinsky M, Pfützner A, Paz-Pacheco E,. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–622
   PubMed Web of Science ®Google Scholar
• . Hollander P, Li J, Allen E, Chen R; CV181-013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–4819
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB,. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Woerle HJ, Neumann C, Zschau S,. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–285
   PubMed Web of Science ®Google Scholar
• . Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881–885
   PubMed Web of Science ®Google Scholar
• . Burgers JS, Bailey JV, Klazinga NS, Van Der Bij AK, Grol R, Feder G. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care. 2002;25(11):1933–1939
   PubMedGoogle Scholar
• . Brunton S. Implementing treatment guidelines for type 2 diabetes in primary care. Postgrad Med. 2009;121(2):125–138
   PubMed Web of Science ®Google Scholar
• . Chacra AR, Tan GH, Apanovitch S, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–1406
   PubMed Web of Science ®Google Scholar
• . Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy. 2004;24:606–620
   PubMed Web of Science ®Google Scholar
• . International Diabetes Federation. Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation, 2005. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed October 26, 2009
   Google Scholar
• . Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–1232
   PubMed Web of Science ®Google Scholar
• . Fleck P, Mekki Q, Kipnes M, Wilson C, Pratley R. Efficacy and safety of alogliptin and glyburide combination therapy in patients with type 2 diabetes. Abstract 76. Diabetologia. 2008;51( suppl 1):S1–S588
   PubMedGoogle Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2008
   Google Scholar
• . DeFronzo R, Hissa MN, Garber AJ,. Once daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D. Diabetes. 2009;58( suppl 1)
   Google Scholar
• . Williams-Herman D, Johnson J, Teng R,. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569–583
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205
   PubMed Web of Science ®Google Scholar
• . Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res. 2009;41(12):905–909
   PubMedGoogle Scholar
• . Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med. 2007;24:955–961
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Fonseca V, Zinman B,. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–166
   PubMed Web of Science ®Google Scholar
• . Goke B, Hershon K, Kerr D,. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892–895
   PubMed Web of Science ®Google Scholar
• . Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11(6):589–595
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(6):571–578
   PubMedGoogle Scholar
• . International Diabetes Federation. The Economics of Diabetes: Human and Social Effects. http://www.worlddiabetesday.org/files/docs/Economicaspects.pdf. 2006. Accessed December 3, 2009
   Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO,; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192
   PubMed Web of Science ®Google Scholar